Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
AMLX Stock Chart & Stats
$14.11
-$0.14(-3.78%)
At close: 4:00 PM EST
$14.11
-$0.14(-3.78%)
Day’s Range― - ―
52-Week Range$3.00 - $17.49
Previous CloseN/A
Volume98.90K
Average Volume (3M)1.24M
Market Cap
$1.55B
Enterprise Value$1.03B
Total Cash (Recent Filing)$316.98M
Total Debt (Recent Filing)$5.96M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
May 07, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding109,819,570
10 Day Avg. Volume930,772
30 Day Avg. Volume1,236,484
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.74
Price to Sales (P/S)0.00
P/FCF Ratio-9.25
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-51.25
Enterprise Value/Ebitda-7.15
Forecast
1Y Price Target
$23.14Price Target Upside64.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.35
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EvidenceAnalyst notes that multiple earlier studies and a completed Phase III Lucidity trial showing consistent reductions in hypoglycemic events reduce development risk and raise the likelihood of regulatory approval.
Market OpportunityAnalyst highlights a substantial addressable population of post-bariatric patients, including many likely undiagnosed, supporting meaningful commercial potential and pricing consistent with rare-disease peers.
Regulatory And Commercialization ReadinessAnalyst emphasizes regulatory designations, prior FDA agreement on the approval pathway, and company preparations for filings and commercial infrastructure as factors that de-risk a potential launch.
Bears Say
Durability Of Treatment EffectAnalyst flags uncertainty about the long-term durability of treatment benefit, which lowers the probability-weighted likelihood of clinical and commercial success.
Evidence Quality And Placebo RiskAnalyst cautions that earlier studies were small, uncontrolled, and open-label, increasing uncertainty from potential placebo effects and heightening reliance on results from the randomized Phase III trial.
Financing RiskAnalyst warns that high cash burn and a limited cash runway create material financing risk that may force dilutive capital raises or delay development timelines.
Amylyx Pharmaceuticals Inc News
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $3.00 and its highest was $17.49 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Amylyx Pharmaceuticals Inc’s market cap is $1.55B.
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is May 07, 2026 which is in 63 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Mar 03, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.352 by $0.052.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc pays a Quarterly dividend of $0.42 which represents an annual dividend yield of N/A. See more information on Amylyx Pharmaceuticals Inc dividends here
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -0.33.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 109,819,570 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.352. Following the earnings report the stock price went down -7.778%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amylyx Pharmaceuticals Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.14 (64.02% Upside)
$23.14 (64.02% Upside)
Blogger Sentiment
Bullish
AMLX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 5.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
370.33%
12-Months-Change
Fundamentals
Return on Equity
-56.52%
Trailing 12-Months
Asset Growth
44.68%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
AMLX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive progress: pivotal trial enrollment complete, clear timelines (top-line Q3 2026), expanded pipeline (AMX318 nomination), AMX114 Fast Track and favorable safety, and a cash runway into 2028. Near-term cautions include a reduced cash balance versus the prior quarter, a $4M milestone payment, modeled placebo/powering conservatism, and the binary risk around the Phase III readout and subsequent regulatory/ commercialization steps. Overall, the positives — clinical progress, pipeline expansion, cost discipline, and adequate cash runway — outweigh the near-term operational and clinical uncertainties.View all AMLX earnings summariesAMLX Stock 12 Month Forecast
Average Price Target
$23.14
▲(64.02% Upside)
Technical Analysis
BioCryst
―
Dianthus Therapeutics
―
Harmony Biosciences Holdings
―
Pharvaris
―
Biohaven Ltd.
―
Ownership Overview
7.51% Insiders
23.23% Mutual Funds
4.41% Other Institutional Investors
49.87% Public Companies and
Individual Investors